we could rarely choose one member of a drug class over another in order to reduce the risk of adverse interactions. But for many drug classes, including the statins, we do have sufficient information to choose members of the class that will reduce the drug interaction risk in specific patients. To blur these differences is to put patients at greater risk of a preventable adverse outcome.
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Efficacy of Simvastatin and Ezetimibe in Treating Hypercholesterolemia
In a recent editorial published in JACC, Dr. Sacks summarized the efficacy of co-administration of simvastatin and ezetimibe, a novel cholesterol absorption inhibitor with a mechanism of action that is complementary to statins (1, 2) . I appreciate the opportunity to provide some additional data, likely not available at the time Dr. Sacks drafted his editorial, to clarify some of the estimates provided by Dr. Sacks (2) . Dr. Sacks took a hypothetical patient, with a pretreatment low density lipoprotein cholesterol (LDL-C) level of 190 mg/dl, and calculated LDL-C reductions and relative risk reduction (RRR) estimates for simvastatin alone and simvastatin/ezetimibe coadministration. It should be pointed out that the calculated LDL reductions and RRR estimates for simvastatin alone and simvastatin/ezetimibe in the editorial are actually too low and underestimate the benefit of using ezetimibe with a statin compared to a statin alone. This is due to the iterative use of the estimated 6% reduction of LDL-C per doubling of simvastatin relative to LDL-C values that were already reduced by simvastatin treatment. The same issue applies with respect to the calculation of anticipated incremental lowering based on addition of ezetimibe. Assuming a 14% reduction with ezetimibe, when ezetimibe is added to the hypothetical patient already on 20 mg of simvastatin with an LDL-C of 125 mg/dl, the reduction of LDL-C by 14% (of 190, not 125 mg/dl) would result in a further decrease in LDL-C of 26.6 mg/dl, bringing the patient to below the goal of Ͻ100 mg/dl without additional simvastatin titration.
The estimated efficacy from the above analysis is highly consistent with the reported 27% reduction in LDL-C relative to baseline (24% relative to placebo) observed when ezetimibe was added to ongoing simvastatin therapy (3) . The data from the clinical trials of initiation of ezetimibe with both simvastatin and atorvastatin indicate that 10 mg of ezetimibe added to either statin produces incremental LDL-C lowering similar to that produced by 80 mg of the corresponding statin, an additional reduction that would require an 8-fold increase in statin dosage to be achieved by titration (4) .
Dr. Sacks makes clearly important points about balancing benefit and potential harm, including the fact that statin-related adverse effects are dose dependent and occur more commonly at the highest doses (5). Although the long-term safety experience with ezetimibe is more limited, the profile to date is very encouraging, particularly with respect to the lack of any incremental risk with respect to the most worrisome statin-related side effects, namely myopathy and rhabdomyolysis. Thus, considering the large numbers of patients not at NCEP ATP III therapeutic goals as well as the well-recognized reluctance of many physicians to titrate, I believe that co-administration of ezetimibe with low-dose statins provides a valuable new option for treatment of hypercholesterolemia.
